CN107496420B - Application of cyclopiazonic acid alkaloid compound - Google Patents
Application of cyclopiazonic acid alkaloid compound Download PDFInfo
- Publication number
- CN107496420B CN107496420B CN201710748797.7A CN201710748797A CN107496420B CN 107496420 B CN107496420 B CN 107496420B CN 201710748797 A CN201710748797 A CN 201710748797A CN 107496420 B CN107496420 B CN 107496420B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- cyclopiazonic acid
- application
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 cyclopiazonic acid alkaloid compound Chemical class 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 240000006439 Aspergillus oryzae Species 0.000 abstract description 9
- 235000002247 Aspergillus oryzae Nutrition 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 239000007787 solid Substances 0.000 abstract description 5
- CNZIQHGDUXRUJS-UHFFFAOYSA-N Cyclopiazonic acid Natural products CC(=C/1C(=O)C2C3C(Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O)O CNZIQHGDUXRUJS-UHFFFAOYSA-N 0.000 abstract 1
- CNZIQHGDUXRUJS-DQYPLSBCSA-N alpha-cyclopiazonic acid Natural products CC(O)=C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O CNZIQHGDUXRUJS-DQYPLSBCSA-N 0.000 abstract 1
- ZKSIPEYIAHUPNM-ZEQRLZLVSA-N butobendine Chemical class C([C@H](CC)N(C)CCN(C)[C@@H](CC)COC(=O)C=1C=C(OC)C(OC)=C(OC)C=1)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZKSIPEYIAHUPNM-ZEQRLZLVSA-N 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 238000001819 mass spectrum Methods 0.000 abstract 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000014511 neuron projection development Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000004090 neuroprotective agent Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229930189266 speradine Natural products 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 101150091922 APO gene Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 102000000728 Nerve growth factor-like Human genes 0.000 description 1
- 108050008149 Nerve growth factor-like Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method and a new application of cyclopiazonic acid compounds. Aspergillus oryzae is fermented in solid or liquid state, the fermented product is separated and purified, and 3 compounds prepared by the method are characterized by applying the technologies of mass spectrum, nuclear magnetic resonance spectrum, infrared spectrum and the like and documents. The invention also provides application of the cyclopiazonic acid compound in preparing a medicament for preventing and/or treating neurodegenerative diseases.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a new application of cyclopiazonic acid alkaloid compounds from aspergillus oryzae in medicines for preventing and/or treating neurodegenerative diseases.
Background
With the coming of the age-old population age, neurodegenerative diseases tend to rise year by year, have higher morbidity and seriously threaten the life quality and body health of middle-aged and elderly people. Neurodegenerative diseases are a group of diseases caused by loss of neurons and/or their myelin, the main pathological features are neuronal loss and dysfunction, and can be classified into acute neurodegenerative diseases (mainly including cerebral ischemia, brain injury, epilepsy, and the like) and chronic neurodegenerative diseases (including alzheimer's disease, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, different types of spinocerebellar ataxia, Pick's disease, and the like).
At present, no effective treatment method for neurodegenerative diseases exists, and the neuroprotective agent is mainly adopted for clinical treatment. The common neuroprotective agents include glutamate antagonists, anti-inflammatory factors, calcium channel blockers, free radical scavengers, GABA receptor antagonists, 5-hydroxytryptamine antagonists, etc., which are limited to symptomatic relief with most of the side effects evident. Therefore, the development of effective neuroprotective drugs becomes a research hotspot for preventing and treating neurodegenerative diseases.
The prevalence studies show that the number of Alzheimer's disease cases in the United states in 2000 is 450 ten thousand. Every 5 years of age, the percentage of patients with senile dementia will increase 2-fold, i.e. the prevalence is 1% in the 60-year-old population and 30% in the 85-year-old population. Senile dementia is a group of primary degenerative brain degenerative diseases with unknown causes, and the currently accepted pathogenesis is mainly two: (1) since the abnormality of the pre-amyloid protein causes the protein component to leak out of the cell membrane, leading to neurofibrillary tangles and cell death, the gene is located on chromosome 21 (Arch Gen Psychiatry, 2005; 62(11): 1186-92.). (2) An increase in APO-E4, in relation to the gene for apolipoprotein E (APO-E4), is able to counteract the function of APO-E2 or APO-E3. APO-E4 decreased the stability of the nerve cell membrane, leading to neurofibrillary tangles and cell death. The probability of the APO-gene being homozygous is higher than that of heterozygotes (Proc. Natl. Acad. Sci. USA, 2005; 102(4): 1211-6). Therefore, promoting repair and regeneration of damaged nerves is a problem to be solved urgently.
Disclosure of Invention
The invention aims to provide a new application of cyclopiazonic alkaloid compounds derived from Aspergillus oryzae (Aspergillus oryzae).
The cyclopiazonic acid alkaloid compound can be used for preparing medicines for preventing and/or treating neurodegenerative diseases.
The cyclopiazonic acid alkaloid compound can be any one of the following 1-3:
pharmaceutically acceptable salts, esters and solvates of the above formulas I-III are also within the scope of the invention.
The invention also provides a preparation method of the cyclopiazonic acid alkaloid compound, which comprises the following steps:
(1) inoculating Aspergillus oryzae (Aspergillus oryzae) strain to slant of agar culture medium in PDA test tube, and pre-culturing; the conditions of the preculture were: culturing at 25 deg.C in dark for 7 days (PDA culture medium composition: potato 200g, glucose 20g, agar powder 16g, purified water to volume of 1L (pH is natural)).
(2) After the mycelia grow over the whole inclined plane, transferring the mycelia into a liquid culture medium under aseptic conditions for culture to obtain a seed culture solution; the culture conditions were: culturing at 25 deg.C in dark for 7 days. Liquid culture medium: glucose 4.0g/L, Malt Extract 10.0g/L, Yeast Extract 4.0g/L, and water to volume of 1L; yeastextract (yeast extract) was purchased from Oxoid Ltd, lot 1074139.
(3) And respectively inoculating 10 ml of seed culture solution into sterilized 500 ml triangular flasks filled with solid culture medium, inoculating 10 flasks, culturing at 25 ℃ in the dark for 40 days (the solid culture medium consists of 80g of long-shaped rice and 120ml of water).
(4) After fermentation, 3L of organic solvent is added into a triangular flask, soaking and extracting are carried out for one week at normal temperature, extraction is carried out repeatedly for 3 times, and organic solvent extracting solutions are combined and distilled under reduced pressure and dried to obtain 80g of extract.
(5) The organic solvent extract was subjected to silica gel open column chromatography (Qingdao ocean chemical Co., Ltd., 200-300 mesh, column chromatography silica gel 150 g; phi 4.5 × 80cm) and n-hexane-ethyl acetate gradient elution (100:0,80:1,50:1,30:1,20:1,10: 1; v/v), dichloro-methanol mixed solvent gradient elution (100:0,100:1,80:1,50:1,30:1,20:1,10:1,5:1,3:1,2: 1; v/v), 5000 ml of each gradient elution solvent was collected as one fraction per 500 ml, and the fraction eluted from n-hexane-ethyl acetate 20:1 was concentrated and dried under reduced pressure, and then subjected to reverse phase column gradient elution (methanol-water ODS 30%, 40%, 50%, 60%, 70%, 80%, 100%).
(6) Gel fraction LH20 (dichloro-methanol 1:1) eluted with 40% methanol-water gave compound of formula I (compound 1).
(7) The 40% methanol-water eluted fraction was recrystallized from methanol to give the compound of formula II (Compound 2).
(8) The second fraction eluted with dichloro-methanol 50:1 was concentrated under reduced pressure and separated by HPLC (38% acetonitrile-water, YMC-ODS C18 column; 5 μm; 9.4 × 250mm) to give the compound of formula III (Compound 3).
In the method of the present invention as described above, it will be understood by those skilled in the art that the organic solvent includes various water-insoluble organic solvents which are liquid at room temperature, such as petroleum ether, chloroform, ethyl acetate, acetone, methanol, etc., and the organic solvent in step (4) is ethyl acetate.
The invention provides a method for preparing compounds 1-3 by Aspergillus oryzae fermentation, and provides application of the compounds 1-3 in preparation of medicines for treating neurodegenerative diseases, and compared with other medicines for treating neurodegenerative diseases reported in literatures, the method has obvious activity. The invention provides a candidate compound for researching and developing new neurodegenerative disease medicines.
Drawings
FIG. 1 is a graph of the effect of varying concentrations of Compound 1 on the neurite outgrowth of undifferentiated PC12 cells.
FIG. 2 is a representative graph of the effect of varying concentrations of Compound 1 on the neurite outgrowth of undifferentiated PC12 cells.
FIG. 3 is a graph of the effect of different concentrations of Compound 2 on the neurite outgrowth of undifferentiated PC12 cells.
FIG. 4 is a representative graph of the effect of different concentrations of Compound 2 on the neurite outgrowth of undifferentiated PC12 cells.
FIG. 5 graph of the effect of different concentrations of Compound 3 on the neurite outgrowth of undifferentiated PC12 cells.
FIG. 6 is a representative graph of the effect of different concentrations of Compound 3 on the neurite outgrowth of undifferentiated PC12 cells.
Detailed Description
The present invention will be described in further detail with reference to examples, but the present invention is not limited thereto.
The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and biomaterials, if not specifically indicated, are commercially available.
Example 1 cultivation of Aspergillus oryzae strains, isolation of Compounds
(1) Activating and culturing strain
Inoculating aspergillus oryzae strain to a slant of a PDA test tube agar culture medium for pre-culture; the conditions of the preculture were: culturing at 25 deg.C in dark for 7 days (PDA culture medium composition: potato 200g, glucose 20g, agar powder 16g, purified water to volume of 1L (pH is natural)). After the mycelia grow over the whole inclined plane, transferring the mycelia into a liquid culture medium under aseptic conditions for culture to obtain a seed culture solution; the culture conditions were: culturing at 25 deg.C in dark for 7 days. Liquid culture medium: glucose 4.0g/L, Malt Extract 10.0g/L, Yeast Extract 4.0g/L, and water to volume of 1L; yeastextract (yeast extract) was purchased from Oxoid Ltd, lot 1074139.
And respectively inoculating 10 ml of seed culture solution into sterilized 500 ml triangular flasks filled with solid culture medium, inoculating 10 flasks, culturing at 25 ℃ in the dark for 40 days (the solid culture medium consists of 80g of long-shaped rice and 120ml of water).
(2) And extraction and separation of the compound
After fermentation, 3L of ethyl acetate is added into a triangular flask, soaking and extraction are carried out for one week at normal temperature, extraction is carried out for 3 times repeatedly, the combined ethyl acetate extract is subjected to reduced pressure distillation and drying to obtain 80g of extract, the ethyl acetate extract is subjected to silica gel open column chromatography (200-300 mesh, column chromatography silica gel 150g, phi 4.5 3580 cm) to obtain 80g of extract, n-hexane-ethyl acetate gradient elution (100:0,80:1,50:1,30:1,20:1,10:1, 2: 1; v/v), dichloro-methanol mixed solvent gradient elution (100:0,100:1,80:1,50:1,30:1,20:1,10:1,5:1,3:1,2: 1; v/v) is carried out for 5000 ml of each gradient elution solvent, the fraction eluted by each 500 ml of n-ethyl acetate 20:1 is collected, subjected to reduced pressure concentration and drying, the fraction eluted by reversed phase ODS column gradient elution (30%, 50%, 60%, 70%, 80%, 40%.
The structure of the compound: the structural formula of the compound of formula I (compound 1) is:
the structural formula of the compound of formula II (compound 2) is:
the structural formula of the compound of formula III (compound 3) is:
physical Properties of the Compounds:
the compound of formula I is yellow powder and has specific rotation luminosity value of α]25D=-94.39(c 0.14CDCl3);CD(c 4.2×10-5M,CDCl3)λmax(△ε)295(-5.2),325(-4.1).HRESIMS m/z339.1705[M+H]+(ii) a The structure of the compound is determined to be the same as Bissecorehydrocyclopedic acid according to the physicochemical properties, hydrogen spectrum and carbon spectrum data of the compound and the numerical comparison of the compound and the reference (Tetrahedron 26(1970) 5239-5246).
A compound of formula II: a light yellow powder; HRESIMS M/z 367.1229[ M + H ]]+(ii) a Based on the physicochemical properties, hydrogen spectrum and carbon spectrum data of the compound, and compared with the reference value (Heterocycles 7(2014)1662-1669),the structure of the compound was determined to be identical to Speradine E.
A compound of formula III: a light yellow powder; specific rotation photometric value(c 0.26 MeOH); the structure of the compound is determined to be the same as Speradine D according to the physicochemical properties, hydrogen spectrum and carbon spectrum data of the compound and the numerical comparison with the reference (Tetrahedron 71(2015)3522e 3527).
TABLE 1 NMR data
Example 2.
Growth promoting effect of undifferentiated PC12 cell process by using compounds of formula I-III
(1) The experimental principle is as follows: under the action of nerve growth factor, the undifferentiated PC12 cell can enlarge sensory neuron and sympathetic neuron, accelerate mitosis, increase the number of nerve cells and induce nerve fiber to grow directionally. It also increases the number of neurons surviving, stimulates the development of neuronal soma and dendrites, increases the density of nerve fibers in the innervating target area, and has protective effect on injured neurons. This experiment was based on the above principle to see if the compound had a nerve growth factor-like effect and promoted growth of undifferentiated PC12 cell process.
(2) Experimental procedure all compounds were dissolved in 10-2M with 100% DMSO, digested with undifferentiated PC12 cells, suspended in DMEM medium (Gibco) containing 5% fetal calf serum (Gibco), 10% horse serum (Gibco) and incubated at 8 × 104cells/ml undifferentiated PC12 cells were seeded in 12-well plates at a volume of 1 ml/well in a medium containing 5% CO2Culturing in a constant temperature incubator at 37 ℃. After 24 hours of culture of undifferentiated PC12 cells, the culture medium of each group was replaced with serum-free DMEM. The test compound and NGF (Upstate) were added to the administration group and the positive control group at the corresponding concentrations, and the culture medium was added to the normal control group, followed by incubation for 48 hours. After 48 hours incubation, observing synaptic growth under a microscopeAnd photographing a growth state image.
(3) The experimental results are as follows: the compounds 1-3 have potential effect of promoting synaptic growth of undifferentiated PC12 cell at 25, 50 and 100. mu.M. (FIGS. 1 to 6)
Example 3.
Repair of damaged PC12 cells by Compounds of formulae I-III
Cell culture: the PC12 cell strain is inoculated in a culture bottle by DMEM medium containing 10% fetal calf serum, 100U/ml penicillin and 100U/ml streptomycin, the culture conditions of a CO2 cell culture box are 37 ℃, the concentration of 5% CO2 and the saturation humidity, and the passage or inoculation is started when the cells grow to about 80%. And (4) observing the growth condition of the cells by an inverted microscope, and taking the cells in the logarithmic growth phase for experiment.
Medicine treatment and grouping, wherein the cells are divided into 5 groups in total, medicine intervention is carried out after 12H of serum-free culture medium inoculation, ① positive medicine control group comprises luteolin, ② negative control group comprises 400 mu mol/L H2O2Making mold liquid 100 mul/hole, acting for 4H, ③ compound group 400 mul mol/L H2O2+ 0.1. mu.M compound. After 24h of action, 10 mu of LCCK8 apoptosis detection solution is added into each well, and the absorbance is measured at 450nm after 4 h.
TABLE 2 repair of damaged PC12 cells by Compounds of formulae I-III
Claims (2)
1. The application of the cyclopiazonic alkaloid compound as the only active component in the preparation of the medicine for preventing and/or treating the neurodegenerative diseases is senile dementia, and is characterized in that: the compound is one or more of a compound shown in a formula I, a compound shown in a formula II or a compound shown in a formula III;
the structural formula of the compound of the formula I is as follows:
the structural formula of the compound of the formula II is as follows:
the structural formula of the compound of the formula III is as follows:
2. use according to claim 1, wherein the pharmaceutical dosage form comprises a tablet, capsule, oral liquid, emulsion, injection, suspension, tincture, granule or aerosol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710748797.7A CN107496420B (en) | 2017-08-25 | 2017-08-25 | Application of cyclopiazonic acid alkaloid compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710748797.7A CN107496420B (en) | 2017-08-25 | 2017-08-25 | Application of cyclopiazonic acid alkaloid compound |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107496420A CN107496420A (en) | 2017-12-22 |
CN107496420B true CN107496420B (en) | 2020-07-07 |
Family
ID=60693938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710748797.7A Active CN107496420B (en) | 2017-08-25 | 2017-08-25 | Application of cyclopiazonic acid alkaloid compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107496420B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111139189B (en) * | 2020-01-14 | 2022-04-19 | 浙江工业大学 | Aspergillus WBX-38 and application thereof in production of cyclopiazonic acid |
CN114409660B (en) * | 2022-01-27 | 2023-03-17 | 云南中烟工业有限责任公司 | CPA type indole alkaloid compound and preparation method and application thereof |
CN114409661B (en) * | 2022-01-27 | 2023-02-28 | 云南中烟工业有限责任公司 | Indole alkaloid compound and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078995A2 (en) * | 2003-03-04 | 2004-09-16 | Neurogenetics, Inc. | Methods of modulating and of identifying agents that modulate intracellular calcium |
EP2200607A4 (en) * | 2007-09-10 | 2012-02-22 | Calcimedica Inc | Compounds that modulate intracellular calcium |
US8895511B2 (en) * | 2009-11-24 | 2014-11-25 | St. Jude Children's Research Hospital | Use of sarcoplasmic CA2+-ATPase type 2 protein for diagnosing and treating learning or mental disorders |
WO2014071042A1 (en) * | 2012-10-31 | 2014-05-08 | The Trustees Of Columbia University In The City Of New York | Methods for identifying candidates for the treatment of neurodegenerative diseases |
KR20170126031A (en) * | 2012-11-13 | 2017-11-15 | 난트 홀딩스 아이피, 엘엘씨 | Calcium flux agonists and methods therefor |
CN104370916B (en) * | 2014-05-14 | 2016-08-24 | 福州大学 | Come from indoles terpene speradine B and the application of aspergillus oryzae |
CN104387396B (en) * | 2014-05-14 | 2016-08-24 | 福州大学 | Come from indole terpene speradine E and the application of aspergillus oryzae |
CN104370917B (en) * | 2014-05-14 | 2016-08-24 | 福州大学 | Come from indole terpene speradine H and the application of aspergillus oryzae |
-
2017
- 2017-08-25 CN CN201710748797.7A patent/CN107496420B/en active Active
Non-Patent Citations (1)
Title |
---|
Marine derived pharmaceuticals- Development of natural health products from marine biodiversity;Yogesh Murti等;《International Journal of ChemTech Research》;20101231;第2卷(第4期);第2198-2217页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107496420A (en) | 2017-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107496420B (en) | Application of cyclopiazonic acid alkaloid compound | |
US11440931B2 (en) | Crocins compounds and uses thereof | |
CN108456168B (en) | Class C19Diterpene alkaloid and application thereof | |
CN105198885A (en) | Compound communesin I with anti-arrhythmias activity, and preparation method and application thereof | |
AU2018314471A1 (en) | 4-OXO-Alkylated tetramic acid compound, preparation method therefor and use thereof | |
CN110590873B (en) | Albizzia julibrissin new lignan compound | |
CN109793765A (en) | Application of the Ramulus et Folium Picrasmae in preparation prevention and treatment neurodegenerative disease drug or health care product | |
CN111848565B (en) | Monoterpene bishydroxycoumarin compound, pharmaceutical composition, preparation method and application thereof | |
CN106905317B (en) | 4- replaces Sampangine alcaloid-derivatives and its synthetic method and application | |
CN114230582B (en) | Novel securinine dimer and preparation method and application thereof | |
CN114209716B (en) | Application of modified lysosome in preparing medicines for treating protein misfolding or processing diseases | |
CN106966887A (en) | Compound separated in colletotrichum gloeosporioides Penz and preparation method thereof and purposes | |
CN112940001A (en) | Phthalide isoquinoline alkaloid and preparation method and application thereof | |
CN114617922B (en) | Application of lycium ruthenicum in preparation of medicines for resisting neurodegenerative diseases | |
CN113387788A (en) | Cavity ketone compound and preparation method and application thereof | |
CN105796579A (en) | Anti-senile brain dementia drug | |
CN107540549B (en) | anti-Alzheimer disease compound in secondary metabolites of aspergillus terreus and separation and preparation method thereof | |
CN104774239B (en) | More piece spore viridin compounds and application thereof | |
CN115518069B (en) | Application of hexahydrobenzophenanthridine alkaloids in protecting dopamine neurons | |
CN101974046B (en) | New natural antipodal kaurane derivative and preparation method and application thereof | |
CN110604731B (en) | Application of compound Aspergillus G in preparation of neuroprotective drugs | |
CN118787652A (en) | Application of ursane-type triterpene derivative in preparation of medicine for treating nervous system diseases | |
CN117695374B (en) | Biological medicine for treating parkinsonism | |
CN115093427B (en) | Medicine for treating Alzheimer disease and related diseases causing cognitive disorder | |
CN104224796A (en) | Application of oleanane triterpene ester derivative in preparation for anti-neurodegeneration medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |